Generated by AI
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers. The company’s work is aimed at targeting cancer pathways involved in tumor growth, survival, and resistance to standard treatments. Actuate Therapeutics also explores applications in cancer types and related disease areas where conventional options remain limited, positioning it within the oncology drug development segment of the healthcare market. Headquartered in Fort Worth, Texas, Actuate Therapeutics concentrates on advancing investigational medicines through early and mid-stage development, with a business model built around translational research, clinical testing, and potential future commercialization of targeted therapies.
The latest articles about ACTU.
Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposuresTreatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cellsFindings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet
- Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model - Phase 1/2 clinical trial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027 CHICAGO and FORT WORTH, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatm
Summary of Nov 18's posts. Generated by AI.
No summary yet.
Summary of Nov 18's posts. Generated by AI.
No summary yet.
Summary of Nov 18's posts. Generated by AI.
Investors talking about ACTU also mention these. Each card shows that asset’s own numbers for the past 24 hours.